KOE:206650

EuBiologics Co., Ltd. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:23 UTC

Last close

n/aKRW

Market data

7.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
27.7%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
29.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.91x

-8.10x

-9.83x

0.24x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales2.91x
Its own average over 10 years, 51.23B.
Profit-8.10x
Its own average over 10 years, -5.09B.
Free cash flow-9.83x
Its own average over 10 years, -4.43B.
Debt0.24x
Its own average over 10 years, 16.76B.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -9.83 times.

Sales is 2.91 times its own 10-year average; Profit is -8.10 times its own 10-year average; Free cash flow is -9.83 times its own 10-year average; Debt is 0.24 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average2.91
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 10-year average-8.10
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 10-year average-9.83
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 10-year average0.24
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW